HME News Reports: Abbott Gains FDA Clearance for Dual Sensing Technology, Marking New Step in DKA Prevention

August 30, 2026

HME News USA

Overview

HME News reports Abbott has received FDA authorization for its Libre Duo 10 Day system, which continuously monitors both glucose and ketones. This biowearable is designed to alert patients to rising ketone levels, crucial for preventing diabetic ketoacidosis (DKA). A physician emphasized the significance of continuous ketone background data for earlier DKA awareness and intervention.

In Depth

Key Findings

On August 27, 2026, HME News reported that Abbott’s Libre Duo 10 Day system received authorization from the U.S. Food and Drug Administration (FDA). This system, heralded as the world’s first device for continuous dual glucose-ketone monitoring in diabetes patients, signifies a major advancement, particularly in the prevention of diabetic ketoacidosis (DKA). Patients can now receive real-time data and alerts regarding potential risks through a small, wearable patch on the arm.

Technical and Clinical Details

The Libre Duo 10 Day system integrates a high-precision sensor for beta-hydroxybutyrate (BHB), the primary ketone body marker, alongside its continuous glucose monitoring (CGM) capabilities. This enables users to track not only blood glucose fluctuation patterns but also trends in ketone levels. A prominent diabetologist quoted in the article highlighted the profound clinical significance: ‘The ability to continuously collect background data on ketone levels is critical for earlier recognition and intervention in DKA risk.’ This feature is expected to significantly improve patient safety, given that DKA can become life-threatening if left unchecked. The continuous nature of the monitoring provides a dynamic view of metabolic status, allowing for timely adjustments to treatment or lifestyle.

Background and Industry Context

In diabetes management, while glycemic control is paramount, patients, especially those with Type 1 diabetes or insulin-dependent Type 2 diabetes, face a persistent risk of DKA due to insulin deficiency or during sick days. Traditionally, ketone monitoring has been performed intermittently, making it challenging to track continuous trends. Abbott’s Libre Duo 10 Day bridges this critical gap, offering the first solution that allows patients to continuously assess their DKA risk in their daily lives. This innovation strengthens preventive care strategies in diabetes and has the potential to reduce the incidence of acute medical emergencies and associated healthcare costs.

Strategic Significance and Outlook

This FDA authorization is expected to profoundly impact the future of diabetes management. Patients will be empowered with more comprehensive physiological data, enabling better-informed decisions regarding diet, exercise, and insulin dosing. For healthcare providers, access to continuous ketone and glucose trends from home allows for enhanced telemedicine and personalized care strategies. HME News foresees that such innovative wearable technologies will open new opportunities in the home medical equipment market, likely prompting other companies to accelerate the development of similar multi-analyte biosensor systems to compete in this evolving landscape.

Source: https://www.hmenews.com/article/abbott-gets-fda-clearance-for-dual-sensing-technology

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.